Kingman Regional Medical Center now offers the latest in minimally invasive technology for lung biopsy: the Ion endoluminal system by Intuitive. The Ion system is a robotic-assisted platform made to improve accuracy and efficiency in lung biopsy procedures. “Early diagnosis of lung cancer is key to successful and effective therapy,” said Dr. Ahmed Mahgoub, pulmonologist at Kingman Regional Medical Center. “Unfortunately, we see a higher-than-average incidence of lung cancer in our area, so having this technology available right here in Kingman really benefits our patients.” Mahgoub and other physicians at KRMC have completed thorough training with the Ion system to learn its capabilities. One such feature is Ion’s ability to turn patient CT scans into 3D visualizations of the lung. Using these images as maps, the doctor will know precisely how to navigate through the curves of the patient’s airways to the target area. With the Ion system’s ultrathin catheter and 3D navigation, doctors can maneuver to deep, hard-to-reach areas of the lung to obtain tissue samples. This precision enables doctors to sample an abnormal growth—or lung nodule— at smaller, earlier stages of development for prompt diagnosis and treatment. An estimated 70 percent of lung nodules are in the outer third of the lung, an area full of tight spaces and narrow airways. Because of its size (3.5 millimeters in diameter) and flexibility, the catheter can access those places in the lung. Using the minimally invasive Ion system, a physician inserts the 180-degree articulating catheter through the patient’s mouth or nose. The fiber-optic based technology identifies the catheter’s precise location hundreds of times per second, resulting in real-time location guidance. This approach reduces the risk of complications as compared to a conventional lung needle biopsy, which involves risk for collapsed lung or bleeding. Historically, it has been difficult to safely biopsy small lung nodules—meaning patients had to wait for the nodule to grow to get answers. “This can cause anxiety,” said Dr. Mahgoub. “The Ion system allows us to biopsy nodules when they are small, leading to earlier diagnosis and treatment.” Many people develop lung nodules—and most are not cancerous—but early detection and treatment are vital for cases that are cancerous. KRMC’s Lung Nodule Clinic provides patients with access to the latest diagnostic tools, advanced therapies, and patient-centered support services. For more information, visit azkrmc.com/services.
Kingman Regional Medical Center’s Post
More Relevant Posts
-
Cyanosis Cyanosis is characterized by a blueish discoloration of the skin or mucous membranes. Cyanosis is frequently encountered in clinical practice, and the differential diagnosis of can be challenging as there are many conditions that can cause cyanosis. Diagnosis of cyanosis is based on a careful history, thorough physical examination, and the use of ancillary studies. Since in most instances, the cardiopulmonary system is involved, a focused assessment of both systems is warranted. If a congenital heart condition is suspected, transthoracic and transesophageal echocardiography can be used to evaluate the cardiovascular system. To assess blood flow and shunting, cardiac Doppler is an important diagnostic tool. Pulmonary causes of cyanosis like pneumonia, pleural effusion, and pulmonary embolism can best be evaluated with imaging studies like radiographs, computed tomography scans, and ultrasounds of the chest. If hypoxemia is suspected as a cause of cyanosis, the primary assessment should include pulse oximetry and arterial blood gas. If congenital hemoglobin M is suspected, hemoglobin electrophoresis can best detect this. This activity describes the evaluation, diagnosis, and management of cyanosis and highlights the importance of providing team-based interprofessional care to affected patients. Cyanosis is a pathologic condition that is characterized by a bluish discoloration of the skin or mucous membrane1 [1]. The word cyanosis is a derivative of the word cyan, a blue-green color. The presence of cyanosis can pose a serious diagnostic challenge. A careful and thorough evaluation with the proper diagnostic tools can help discern the cause. Diagnosis of cyanosis is based on a careful history, a thorough physical examination, and the use of ancillary studies. Since in most instances, the cardiopulmonary system is involved in the development of cyanosis, a focused assessment of both systems is warranted. If a congenital heart condition is suspected, transthoracic and transesophageal echocardiography can be used to evaluate the cardiovascular system. To assess blood flow and shunting, cardiac Doppler is a very important diagnostic tool. Other tests include cardiac catheterization, CT scan, and MRI of the heart[9]. Pulmonary causes of cyanosis like pneumonia, pleural effusion, and pulmonary embolism can best be evaluated by using imaging studies like X-Ray, CT Scan, and ultrasound of the chest. If hypoxemia is suspected as a cause of cyanosis, the primary assessment should include pulse oximetry and arterial blood gas. The arterial blood gas shows the partial pressure of dissolved oxygen in the blood as well as the saturation of hemoglobin. The pulse oximeter measures the absorption of light at only two wavelengths which correspond to that of oxyhemoglobin and deoxyhemoglobin. The drawback of measuring only two wavelengths is that it can create a misleading picture when evaluating a patient. #snscollegeofphysiotherapy #snsdesignthinking
To view or add a comment, sign in
-
-
Did You Know that Protecting the Endothelium Can Transform Patient Outcomes in Heart Attacks, Major Surgeries, and Organ Transplants?🛡️❤️🩺 In critical medical interventions such as revascularisation for heart attacks and organ transplants, restoring blood flow is crucial but can paradoxically trigger ischaemia-reperfusion injury (IRI). The endothelium, the inner cellular lining of blood vessels, plays a central role in the pathophysiology of IRI. 🔬 The Endothelial Interface in IRI: During IRI, the sudden rush of blood returns oxygen and nutrients to the tissue, which can lead to a damaging inflammatory response and oxidative stress. The endothelium directly mediates these effects by regulating vascular tone, barrier function and inflammatory responses. Endothelial Dysfunction is characterised by impaired barrier function leading to microvascular leakage that exacerbates tissue damage and can affect the outcome of cardiac surgery, major surgery, trauma, and organ transplantation. 🌟 Therapeutic Insights and Endothelial Protection: Recent scientific studies emphasise the importance of maintaining endothelial integrity through drug-mediated intervention at the molecular level to mitigate the adverse effects of reperfusion, for example via targeting VE-cadherin or Angiopoietin/TIE2 signalling. 🧗 The challenge lies in translating pathophysiological findings from animal studies to clinical practice. Researchers have tirelessly explored ways to prevent reperfusion-related damage, aiming to enhance patient outcomes since the mid-1980s. While clear treatment guidelines remain elusive, emerging trends offer hope for more effective tissue-protecting strategies.🧪🩺 🌐 Broader impact: Promoting endothelial health to prevent ischaemia-reperfusion injury accelerates recovery, improves quality of life for patients, reduces the burden of care for families and lowers healthcare costs for society. Endothelial protection during acute respiratory distress syndrome (ARDS) is the focus of IXION2.0, the clinical trial within the COVend project, and our research will provide important insights into understanding and combating IRI. For a deeper dive into this insightful research, check out the original publication referenced in the post from our team 👉https://lnkd.in/d-299jNa Microvascular Leakage as Therapeutic Target for Ischemia and Reperfusion InjuryReference: Kloka JA, Friedrichson B, Wülfroth P, Henning R, Zacharowski K. Microvascular Leakage as Therapeutic Target for Ischemia and Reperfusion Injury. Cells. 2023;12(10):1345. Published 2023 May 9. doi:10.3390/cells12101345 Special acknowledgement to COVend authors; Dr. Jan Kloka, Benjamin Friedrichson, Petra Wuelfroth and Project Coordinator, Prof. Dr. Dr. Kai Zacharowski ✨ #MedicalResearch #Cardiology #HeartAttack #VascularHealth #ARDS #HealthcareInnovation #OrganTransplantation
To view or add a comment, sign in
-
-
Golden Managment of Neck mass in adult patient 2023: #As CME program with education to all Medical and Surgical staff along with ER,GS Doctors #. - Despite significant progress in clinical diagnostic tools, a thorough and carfull medical history and physical examination of the patient remain the mainstay and still the cornerstones of the workup of a neck mass. - It is important to keep in mind that although neck masses are common in adults and children, the etiology is often considerably different. - Neck masses should be assumed to be malignant until proven otherwise, Metastatic squamous cell carcinoma is the most common malignancy in the adult neck. - In fact, when thyroid masses are excluded, it has been shown that adults with neck masses have an 80% chance of the mass being malignant -Cervical lymph node metastases of squamous cell carcinoma from an unknown primary site constitute about 5% of the total head and neck cancer cases. The management of these patients is still a therapeutic challenge. The 5-year overall survival rate of all patients was 68% . - An endoscopy will be performed either in OPD with local anesthesia or in case of suspicion should be done on operating room under general anesthesia . -The sequences of procedures should be respected and do as follow : FNAc- CT, MRI, or PET (positron emission tomography) scan … - Flexible fiberoptic laryngoscopy(FFOL) in addition to standard indirect laryngoscopy techniques. - Computed tomography is still the most cost-effective imaging modality. - Fine-needle aspiration should be attempted prior to obtaining incisional and/or excisional biopsies. -The optimal opinion, panendoscopy and fine needle aspiration should be the first-line diagnostic approach,could be repeated if negative and still high suspected malignat mass clinically, When cytologic diagnosis proves impossible, the second-line approach must consist of cervical exploration with frozen section examination and excisional biopsy, followed by immediate appropriate treatment. - Core biopsy, Open biopsy—An open biopsy should typically be done only after FNA and/or core biopsy have failed to make the diagnosis. It is the next step to diagnose a neck mass. It is a more invasive procedure, there is a somewhat higher risk for complications,as well increases the risk of recurrence of malignant neoplasms ,as increase the risk of cancer cell seeding and dissemination that, ultimately, worsens a patient's survival. -Treatment options include surgery, radiation therapy with or without chemotherapy, or a combination of these treatments depending on the diagnosis and stage of the disease. #Dr. Anas Ghonem Al Hariri #, #OtoRhinLaryngologist Consultant# #United Arab Emirates # PO Box 57600#
To view or add a comment, sign in
-
HCA Florida Bayonet Point Hospital performs 500th Thrombectomy Those who treat stroke patients all agree: time makes a difference. The quicker a patient suffering from a stroke can get treatment has a direct impact on the eventual outcome and that patient’s future quality of life. Equally important, according to Alison Fowler, director of Diagnostic Imaging and Non-Invasive Cardiology/Neurology Services at HCA Florida Bayonet Point Hospital, is getting the right treatment for stroke. “We’re fortunate here at Bayonet Point Hospital to be able to perform thrombectomies,” Fowler explained. “The work we do here has a tremendous impact on our patient’s eventual return to a more normal life and that is our ultimate goal as caregivers.” So, what is a thrombectomy? The National Institute of Heath defines a thrombectomy as “a mechanical interventional procedure by which a blood clot or thrombus is removed under image guidance using endovascular devices. Thrombectomy is most commonly used in acute cerebral ischemic stroke, although it is also a procedure used for clot removal in acute myocardial infarction and pulmonary embolism. Mechanical thrombectomy utilizes various techniques. Most commonly, it uses different catheter-based therapies, including stent-retrieval, direct aspiration or a combination of both.” In layman’s terms, it is the removal of a blood clot that is restricting blood flow to a portion of the brain, and that’s where Bayonet Point Hospital’s Neuro-Interventional Services team comes in. “Radiology has been around a very long time,” said Fowler. “As technology has gotten better, radiology has gotten better. In the case of treatment for strokes, thrombectomy procedures started in the early 2000’s and have progressed to where we are today. If we can perform the procedure within a few hours of the stroke process we make a huge difference. Radiology enables the physicians to locate where the clot or clots are and get to the area more quickly and with greater precision than ever before. In short, radiology enhances the effectiveness of stroke interventions.” Bayonet Point Hospital recently celebrated performing the 500th thrombectomy with a small ceremony and the creation of a patch for the caregivers’ scrubs commemorating the event. The team expects the need to grow as a thrombectomy becomes the standard treatment for strokes. “Certainly 500 thrombectomies is a milestone and something we’re very proud of but it isn’t where we expect to be in the years to come,” said Fowler. “The more the word gets out about what we can do and what we have done, the more I expect we’ll be asked to perform,” said Erin Rona, supervisor, Special Procedures at Bayonet Point Hospital. Bayonet Point Hospital is a Comprehensive Stroke Center accredited by DNV since June 2018. Bayonet Point Hospital has achieved the highest DNV stroke certification due to its ability to diagnose, treat and care for emergent stroke patients.
To view or add a comment, sign in
-
-
Part 02/02 Unveiling the Triumph Over NETs: An Insightful Account of Modern Treatment Surviving NETs: An Oped Perspective: Surviving NETs can be an incredibly challenging journey, but it's not without hope. As we learn more about these tumors, early detection and advanced treatments continue to improve. Additionally, the power of advocacy and research in the medical community is helping to expand our knowledge of NETs and improve the lives of those living with these diagnoses. The successful treatment of NETs often involves a multi-disciplinary approach, and here, highlighted some of the key components that can make a significant difference in improving the prognosis and quality of life for those diagnosed with carcinoid tumors and other types of NETs. Key Components in Treating NETs: 1. Specialized Medical Team: Having a team of highly qualified specialists, including medical oncologists with expertise in hematology, gastroenterologists, and surgical oncologists, is crucial. They can provide a comprehensive evaluation and develop a personalized treatment plan. 2. Advanced Imaging: Advanced imaging techniques, such as the GA-68 DOTATOC PET-CT scan, can help locate NETs and their specific receptors, enabling more precise diagnosis and treatment planning. 3. Peptide Receptor Radionuclide Therapy (PRRT): PRRT is a groundbreaking treatment for NETs. It involves the use of radioisotopes like Lutetium-177 attached to a molecule that targets NET cells specifically. The radiation targets and destroys the tumor cells while sparing healthy tissue. 4. Surgery: In some cases, surgery may be necessary to remove tumors or manage complications, and it's essential to have experienced surgical oncologists for these procedures. 5. Medications: Medical treatment, including somatostatin analogs and targeted therapies, can help control the growth and symptoms of NETs. 6. Supportive Care: Beyond medical treatments, providing psychological and emotional support for patients and their families is essential for managing the challenges associated with NETs. 7. Research and Clinical Trials: Participation in clinical trials and ongoing research is crucial to advancing our understanding of NETs and developing more effective treatments. It's heartening to see that medical science is making significant strides in the management of NETs, and these advanced procedures and treatments offer hope for higher survival rates and improved quality of life. The personalized approach to treatment, along with the availability of cutting-edge technologies and therapies, is increasing the chances of successfully battling these complex tumors. Furthermore, the support of dedicated healthcare professionals &the continued efforts of the medical community are instrumental in enhancing the outlook for individuals who are facing NETs, including carcinoid tumors. As we learn more about these conditions & apply innovative treatments, the prospects for those affected continue to improve.
To view or add a comment, sign in
-
The role of surgical treatment of recurrent glioblastomas With standard treatment of glioblastoma, the vast majority of cases result in relapse of the disease, for which there is no consensus on the effectiveness of repeat resection. The lack of Level 1 evidence on the efficacy of surgical removal of recurrent glioblastomas (GB) indicates that the problem has not been resolved and stimulates interest in finding ways to combat this disease. Purpose. To study the effect of surgical treatment of a recurrent tumor on the overall life expectancy and post-relapse survival time of patients with glioblastomas. Materials and methods. The analysis was performed on data from 116 patients: 43 (37.1 %) women and 73 (62.9 %) men. The mean age at the time of diagnosis (primary surgery) was 52±12 full years. Surgical interventions were performed between 1999 and 2017. The study group included 50 patients who underwent GB resection. The control group consisted of 66 patients who were not operated on for GB. To achieve group homogeneity for all studied variables, the pseudo-randomization method was used. Statistical analysis was performed using the program SPSS Statistics 26.0. Results. The median overall life expectancy after GB resection was 23.6 [95 % CI=18.1–29.1] months, in the control group — 21.0 [95 % CI=12.8–29.2] months. The fatal outcome for the patients in the study group was simultaneously influenced by two characteristics: the duration of the relapse-free period (p=0.003) and the volume of the recurrent tumor (p=0.050). For the patients in the control group, only the duration of the relapse-free period (p <0.001) was impactful. The median post-relapse survival time was higher in those patients who underwent resection of 95 % or more of the GB volume than in those without surgery: 10.33 months [95 % CI 9.67 — NA months] and 6.33 months [95 % CI 5.07–11.2 months] (p<0.05), respectively. The 2-year survival rate in the group after resection of 95 % or more of the GB volume is more than twice as high as in the non-operated group: 38.5 % and 13.7 %, respectively. Conclusions. Maximum reduction in GB volume appears to be advisable, especially in patients with a long relapse-free period when the formation is localized in the subdominant hemisphere of the brain, without spreading to the corpus callosum. Microsurgical removal of recurrent glioblastomas is an effective method of treating patients in comparison with conservative therapy. https://lnkd.in/eWZgvCmn
To view or add a comment, sign in
-
-
Advancing Surgical Safety with Keystone Perfusion's Cell Saver Services At Keystone Perfusion Services, we are dedicated to providing solutions that improve patient safety and recovery. Our Cell Saver services are crucial for surgical procedures where significant blood loss is anticipated, offering a safe and efficient alternative to traditional blood transfusions. Recent research led by steven frank from Johns Hopkins Medicine highlights the benefits of using autotransfusion over banked blood. The study indicates that blood salvaged and reused during surgery not only reduces the risks associated with red blood cell damage but also promotes quicker patient recovery. Key Findings: Enhanced Cell Functionality: Patients receiving their own recycled blood demonstrate optimal red blood cell functionality, maintaining the ability to effectively deliver oxygen throughout the body immediately post-operation. Reduced Complications: Utilizing recycled blood reduces the risk of hospital-acquired infections, minimizes hospital stays, and decreases mortality rates. Cost-Effectiveness: Autotransfusion is more economical compared to the use of banked blood, which can degrade over time and lose efficacy. Our Cell Saver service ensures that blood collected during surgery is processed meticulously, removing unnecessary constituents and promptly returning purified red cells to the patient. This not only provides a fresher blood supply but also aligns with patients' preferences for using their own blood, minimizing their exposure to potential risks associated with transfusions. Expanding Applications: Originally popularized during the HIV/AIDS crisis, cell salvaging is vital not only in cardiac surgery but also in orthopedics, vascular, trauma, and transplant surgeries—areas where Keystone has demonstrated impactful results. As Eduardo Nunes from the AMERICAN ASSOCIATION OF BLOOD BANKS (AABB) notes, while autotransfusion isn't suitable for every surgical scenario, it represents a "viable alternative treatment" in many cases, particularly those involving significant blood loss. Looking Ahead: Keystone Perfusion is committed to increasing awareness and adoption of cell saver technologies, ensuring that more healthcare providers can offer this life-saving option. By investing in advanced autotransfusion systems, we aim to support hospitals in delivering the highest standard of care. We invite surgeons and healthcare institutions to partner with us in revolutionizing patient care through the use of our Cell Saver services. Together, we can save lives and enhance surgical outcomes with technology that supports patient recovery right from the operating room. For more information on how Keystone Perfusion's Cell Saver services can benefit your operations, visit our website or contact our team directly. Let's make every drop of blood count. www.keystoneperfusion.com #bloodmanagement #perfusion #AABB #autotransfusionist #surgery #bloodusage #cardiacsurgery
To view or add a comment, sign in
-
Peripheral Arterial Interventional Devices Market Analysis, Key Players, Share Dynamic Demand and Consumption by 2023 to 2032 https://lnkd.in/dgGKMRJF Peripheral Arterial Interventional Devices: Peripheral Arterial Interventional Devices are medical devices used in the treatment of peripheral arterial diseases. These diseases affect blood vessels outside the heart and brain, commonly the arteries in the legs. Interventional procedures include angioplasty, stenting, atherectomy, and other techniques to open narrowed or blocked arteries, improving blood flow. Market Overview: The market for peripheral arterial interventional devices is influenced by several factors: Prevalence of Peripheral Arterial Diseases: The increasing prevalence of peripheral arterial diseases, often associated with aging and lifestyle factors, contributes to the demand for interventional devices. Technological Advancements: Ongoing innovations in device design, materials, and imaging technologies can impact the market. Advanced devices that improve procedural outcomes and patient safety may see increased adoption. Market Size and Growth: The market size is influenced by the overall burden of peripheral arterial diseases and the need for interventional treatments. Growth may be driven by advancements in endovascular technologies. Trends: Drug-Coated Devices: The use of drug-coated balloons and stents to reduce the risk of restenosis after interventional procedures. Minimally Invasive Approaches: Growing preference for minimally invasive techniques, reducing patient recovery time and improving overall outcomes. Multidisciplinary Approach: Collaboration among vascular surgeons, interventional radiologists, and other specialists for comprehensive patient care. Challenges: Reimbursement Issues: Challenges related to reimbursement policies for peripheral arterial interventions. Competition: The presence of a competitive market with multiple device manufacturers. Future Outlook: The future outlook for the peripheral arterial interventional devices market may involve continued advancements in technology, personalized treatment approaches, and efforts to address challenges related to reimbursement. As the aging population grows and awareness of peripheral arterial diseases increases, the demand for effective interventional devices is likely to persist. Click Here, To Get Free Sample Report https://lnkd.in/dstm_bnV Market Segmentations: Global Peripheral Arterial Interventional Devices Market: By Company • Medtronic, Inc. • BD • Boston Scientific Corporation • Abbott Laboratories • Cordis • Acotec • Biotronik • Terumo Corporation • Shanghai MicroPort Endovascular MedTech(Group)Co., Ltd. • Cook Medical • Lepu Medical • Zylox-Tonbridge Medical
Peripheral Arterial Interventional Devices Market Analysis, Key Players, Share Dynamic Demand and Consumption by 2023 to 2032
To view or add a comment, sign in
-
Peripheral Arterial Interventional Devices Market Analysis, Key Players, Share Dynamic Demand and Consumption by 2023 to 2032 https://lnkd.in/dgGKMRJF Peripheral Arterial Interventional Devices: Peripheral Arterial Interventional Devices are medical devices used in the treatment of peripheral arterial diseases. These diseases affect blood vessels outside the heart and brain, commonly the arteries in the legs. Interventional procedures include angioplasty, stenting, atherectomy, and other techniques to open narrowed or blocked arteries, improving blood flow. Market Overview: The market for peripheral arterial interventional devices is influenced by several factors: Prevalence of Peripheral Arterial Diseases: The increasing prevalence of peripheral arterial diseases, often associated with aging and lifestyle factors, contributes to the demand for interventional devices. Technological Advancements: Ongoing innovations in device design, materials, and imaging technologies can impact the market. Advanced devices that improve procedural outcomes and patient safety may see increased adoption. Market Size and Growth: The market size is influenced by the overall burden of peripheral arterial diseases and the need for interventional treatments. Growth may be driven by advancements in endovascular technologies. Trends: Drug-Coated Devices: The use of drug-coated balloons and stents to reduce the risk of restenosis after interventional procedures. Minimally Invasive Approaches: Growing preference for minimally invasive techniques, reducing patient recovery time and improving overall outcomes. Multidisciplinary Approach: Collaboration among vascular surgeons, interventional radiologists, and other specialists for comprehensive patient care. Challenges: Reimbursement Issues: Challenges related to reimbursement policies for peripheral arterial interventions. Competition: The presence of a competitive market with multiple device manufacturers. Future Outlook: The future outlook for the peripheral arterial interventional devices market may involve continued advancements in technology, personalized treatment approaches, and efforts to address challenges related to reimbursement. As the aging population grows and awareness of peripheral arterial diseases increases, the demand for effective interventional devices is likely to persist. Click Here, To Get Free Sample Report https://lnkd.in/dstm_bnV Market Segmentations: Global Peripheral Arterial Interventional Devices Market: By Company • Medtronic, Inc. • BD • Boston Scientific Corporation • Abbott Laboratories • Cordis • Acotec • Biotronik • Terumo Corporation • Shanghai MicroPort Endovascular MedTech(Group)Co., Ltd. • Cook Medical • Lepu Medical • Zylox-Tonbridge Medical
Peripheral Arterial Interventional Devices Market Analysis, Key Players, Share Dynamic Demand and Consumption by 2023 to 2032
To view or add a comment, sign in